目的 系统评价补益强心片联合治疗慢性心力衰竭（CHF）患者疗效及安全性。方法 检索中国学术期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、万方数据库（Wanfang Date）、维普中文科技期刊数据库（VIP）、PubMed、Embase、Cochrane Library、Medline等数据库自建库至2022年5月收录的补益强心片联合治疗CHF临床随机对照试验（RCT），采用RevMan 5.4.1及Stata 15.0软件进行Meta分析。结果 纳入13项RCTs，共1 570例患者，其中试验组874例、对照组696例。Meta分析结果显示，与对照组比较，试验组可能明显提高CHF患者的临床有效率[RR=1.16，95% CI （1.11，1.22）]，改善射血分数[MD=4.63，95% CI （4.08，5.18）]，降低N-末端脑钠肽前体[SMD=-2.02，95% CI （-3.02，-1.02）1，增加6 min步行距离[MD=41.34，95% CI （37.50，45.18）]，降低明尼苏达心力衰竭生活质量量表评分[MD=-9.54，95% CI （-10.80，-8.28）]，改善L氏心衰评分[MD=-1.09，95% CI （-1.36，-0.83 1，两组有显著差异（P<0.00001）；降低不良反应[RR=0.28，95% CI （0.12，0.66），P=0.004]。结论 补益强心片联合西医常规治疗较单纯西医常规治疗CHF具有更好的疗效和安全性，但限于纳入文献质量低等不足，需进一步研究加以验证。

Objective To systematically evaluate the clinical efficacy and safety of Buyi Qiangxin Tablets combination therapy for patients with chronic heart failure(CHF).Methods Data were electronically searched from the CNKI, CBM, WanFang, VIP, PubMed, Embase, Cochrane Library, Medline database to collet randomized controlled trails(RCTs) of Buyi Qiangxin Tablets combination therapy for CHF.The retrieval time was from database establishment to May 2022.Meta-analysis was performed using RevMan 5.4.1 and Stata 15.0 software.Results A total of 13 RCTs were included, including 1 570 patients which 874 cases in experimental groups and 696 cases in control groups.Meta-analysis results showed that compared with control group, experimental can significantly improve the clinical efficiency[RR=1.16, 95%CI(1.11, 1.22)], improve the ejection fraction values[MD=4.63, 95%CI(4.08, 5.18)], reduce NT-proBNP[SMD=-2.02, 95%CI(-3.02, -1.02)], extend the distance of 6-minute walk distance[MD=41.34, 95%CI(37.50, 45.18)], reduce the Minnesota heart failure quality of life scale score[MD=-9.54, 95%CI(-10.80, -8.28)], improve L's heart failure score[MD=-1.09, 95%CI(-1.36, -0.83)], which were statistically significant(P<0.000 01);and reduce adverse reactions[RR=0.28, 95%CI(0.12, 0.66), P=0.004].Conclusion The combination of western medicines and Buqi Qiangxin Tablets in combination treatment of CHF has good efficacy and safety over western medicines alone.However, due to the low quality of inclusion literatures and other limitations, more studies are indeed in the future.

R286.2;R972